LepiDyne
Seoul
About LepiDyne
LepiDyne holds a prominent global position in the domain of cancer diagnosis. LepiDyne Co., Ltd. has established clinical networks centered around Seoul National University Hospital and has successfully acquired liver cancer diagnostic and prognostic markers, as well as liver-specific markers. With the integration of a PCR-based diagnostic system, the company aims to make liquid biopsy a standard procedure in routine clinical practice. LepiDyne aspires to penetrate both domestic and global diagnostic markets with its advancements. LepiDyne Co., Ltd. will grow into a cancer blood diagnosis (bio-health) company that can compete in Korea and globally with simple but differentiated products and services.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $5.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2023)
- Website: lepidyne.com
- Phone: (02)-6077-7621
Industries & Categories
Biotechnology, Life Science, Medical, Oncology
Canonical: https://fsome.com/organization/lepidyne-109705 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.